November 24th 2024
Patients experienced similar safety and efficacy if they received first-line or later-line treatment for unresectable hepatocellular carcinoma (u-HCC).
Phase 3 Study Shows Live Biotherapeutic Significantly Reduces CDI Recurrence
November 8th 2022A phase 3 study showed Ferring’s RBX2660, an investigational microbiota-based live biotherapeutic, to be safe and significantly reduce recurrence of Clostridioides difficile infection (CDI) after antibiotic treatment, with a sustained response achieved through 6 months.
Read More
The Department of Veterans Affairs (VA) will give cancer claims priority when a new law takes effect in January 2023; Pfizer is looking to use its COVID-19 profits to grow other blockbusters; the probable loss of Medicaid coverage for millions next year is setting off debate.
Read More
Poor Self-rated Mental Health and Medicare Beneficiaries’ Routine Care-Seeking
Efforts are needed to ensure that Medicare beneficiaries with poor mental health receive regular routine care, which may be facilitated by having a personal doctor.
Read More
Daniel E. Weiner, MD, MS, board certified nephrologist and lead navigator at Tufts Clinical and Translational Science Institute, spoke on the limitations and future potential of value-based payment systems for chronic kidney disease (CKD), including the End-Stage Renal Disease (ESRD) Treatment Choices (ETC) Model and the Kidney Care Choices (KCC) Models.
Watch
Curtis Warfield, MS, senior quality analyst, Indiana State Department of Health, and regional leader of National Kidney Foundation's Kidney Advocacy Committee, spoke on limitations regarding the current process of educating and managing lifestyle interventions for patients with chronic kidney disease (CKD), and how nephrologists can better integrate these strategies.
Watch
Nephrology Director Shares Ups, Downs of Participating in Kidney Care First
November 6th 2022It has been 3 years since new kidney care payment models were announced by HHS, and at a session at Kidney Week 2022, the associate division director of nephrology at the University of Alabama at Birmingham described his organization’s participation in Kidney Care First, one of the value-based care models announced in 2019.
Read More
Jen Gunter, MD, obstetrician and gynecologist, author, and specialist in chronic pain medicine and vulvovaginal disorders, spoke on the change in perspective regarding the medical and scientific community's role in dispelling health care misinformation on social media and in the press.
Watch
Jennifer Green, MD, professor of medicine at Duke University School of Medicine, member of Duke Clinical Research Institute, and EMPA-KIDNEY collaborator, discussed findings of the EMPA-KIDNEY trial presented at Kidney Week 2022, which showed a 28% improvement for patients with chronic kidney disease (CKD) on empagliflozin, whether in reduced mortality from cardiovascular disease or progression of CKD.
Watch
Dr Brent W. Miller on Emerging Technologies in Home Dialysis and Strategies to Improve Uptake
November 4th 2022Brent W. Miller, MD, board certified nephrologist and professor of clinical medicine at Indiana University School of Medicine, discussed new and emerging technologies for at-home hemodialysis and peritoneal dialysis, as well as efforts that have been made to address uptake issues for patients with kidney disease.
Watch
Empagliflozin Cuts Risk of Cardiovascular Death, More Severe CKD by 28%, Study Finds
November 4th 2022Empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, reduced the risk of death or worsening progression of chronic kidney disease (CKD) by 28%, according to results published Friday at Kidney Week 2022.
Read More
A poster presented at the Academy of Managed Care Pharmacy Nexus 2022 showed that patients with recurrent Clostridioides difficile infection (rCDI), who had Medicare Advantage Part D coverage or were enrolled in a commercial health plan were associated with significantly greater health care resource utilization, including emergency department and inpatient visits, compared with those without rCDI.
Read More
Dr Jason Ezra Hawkes Reviews Recent Advances, Unmet Needs in Management of Hidradenitis Suppurativa
November 4th 2022Jason Ezra Hawkes, MD, MS, FAAD, board-certified dermatologist and associate professor of Dermatology at the University of California Davis in Sacramento, spoke on challenges in the management of hidradenitis suppurativa (HS), as well as promising therapies in the pipeline that target specific pathways suggested to play a role in the pathogenesis and pathophysiology of the disease.
Watch
Macitentan Safety, Effectiveness in PAH Confirmed in New Analysis
November 3rd 2022Two data sets from patients with severe pulmonary arterial hypertension (PAH) show the benefits of macitentan (Opsumit) monotherapy despite guidelines calling for combination therapy, even among patients with World Health Organizational functional class I-II disease.
Read More
As Medical Falsehoods Persist, Concerns About Future Pandemic Readiness Grow
November 3rd 2022Physicians and scientists are worried about the future pandemic preparedness, and the reasons why are largely due to social and political influences, according to a keynote speech and panel discussion on the first day of Kidney Week 2022.
Read More
Intermediate Parkinson Disease Associated With Significant Clinical, Economic Burden
November 2nd 2022A poster presented at Academy of Managed Care Pharmacy Nexus 2022 shows that patients with intermediate Parkinson disease place a significant resource burden on the US health care system in regard to treatment, emergency department visits, and admissions to rehabilitation centers.
Read More
Jim Rhodes on How Joining GPBCH Has Led to Advancements in Equitable Health Care for Camden County
November 2nd 2022Jim H. Rhodes, deputy county administrator, Camden County, New Jersey, spoke on how his organization’s membership with the Greater Philadelphia Business Coalition on Health (GPBCH) has aided their value-based initiatives in improving health equity in the region.
Watch
Hidradenitis Suppurativa ED Readmission Linked to Opioid Prescribing, Medicaid Insurance
November 1st 2022Emergency department (ED) readmission was more common than dermatology follow-up among patients with hidradenitis suppurativa (HS) within 30 and 180 days of initially presenting to the ED, with patients with Medicaid coverage and those who had an opioid prescribed were more likely to return.
Read More
Susan E. Quaggin, MD, FASN, president of the American Society of Nephrology (ASN) for the 2021-2022 term, discussed the major focuses and breakthroughs in nephrology to be presented at Kidney Week 2022, which include novel treatments for common and rare kidney diseases, as well as efforts to address disparities for transplant and care access.
Watch
Study Supports Feasibility of Integrating Specialty Pharmacists in Health Systems
October 30th 2022The program, serving patients from rheumatology, dermatology, gastroenterology, allergy, and cardiology clinics, is the first of its kind within the Veterans Health Administration, researchers said.
Read More